Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM15RI)

Drug Name

Ranpirnase Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lung cancer	2C25.0	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ribonuclease (RNase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NTO-1151	DMRYLBW	Cervical cancer	2C77.0	Phase 2	[3]
MazF gene therapy	DMSZ8HT	Human immunodeficiency virus-1 infection	1C62	Phase 1	[4]
AS-1406	DMRYQBE	Solid tumour/cancer	2A00-2F9Z	Terminated	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01184287) A Study Of Ranpirnase(Onconase) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
2	Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008 Jun;8(6):813-27.
3	Clinical pipeline report, company report or official report of Nanotherapeutics.
4	Clinical pipeline report, company report or official report of Takara Bio.
5	WO patent application no. 2005,0657,17, Liquid formulations of antibody conjugates.